Skip to Main Content

A controversial Trump administration plan to lower drug costs by pegging prices to what are paid by several foreign countries is getting pushback from dozens of groups. They argue the proposal would import price controls, restrict patient access, and reduce incentives for medical innovation.

In a letter to House and Senate leaders, the groups maintain the proposal is misguided and would ultimately hurt millions of Medicare B beneficiaries. And so, they urged the lawmakers to end the proposed pilot program and instead consider implementing some of the ideas in a limited fashion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!